Recent Clinical Experience with Oncolytic Viruses

Author(s): O. G. Donnelly, F. Errington-Mais, R. Prestwich, K. Harrington, H. Pandha, R. Vile, A. A. Melcher

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 9 , 2012

Become EABM
Become Reviewer


There has been interest in using viruses to treat cancer for over a century. Recent clinical efforts, driven on by significant preclinical advances, have focussed on the safety of using replication-competent viruses. Recently published clinical trials of six oncolytic viruses (adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus and vaccinia) have added to the accumulating data that endorse oncolytic viruses as a safe and well tolerated treatment approach. Conclusive evidence of efficacy remains to be demonstrated, but randomised clinical trials are now underway.

Keywords: Oncolytic virus, adenovirus, measles, reovirus, vaccinia, cancer, replication-competent viruses

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [1834 - 1841]
Pages: 8
DOI: 10.2174/138920112800958904
Price: $65

Article Metrics

PDF: 19